


S/N 10/049,579

PATENT



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bernt Swedenborn Asbeck et al.
Serial No.: 10/049,579
Filed: February 13, 2002

Examiner: Jeffrey Stucker
Group Art Unit: 1648
Docket: 30394-1064

Title: Bleomycin or Hydroxypyridinon and Virus Inhibiting Combination Pharmaceutical Composition and Methods (as amended)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record.

Because this submission contains only complete copies of articles for which the Examiner cited and provided only an abstract, it is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 13-4213 in order to have this Supplemental Information Disclosure Statement considered.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.


Respectfully submitted,

Date December 13, 2004

By 
Stephen A. Slusher, Reg. No. 43,924

Peacock Myers & Adams, P.C.
P.O. Box 26927
Albuquerque, New Mexico 87125-6927
505 998 6130
Customer No. 005179

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 13 day of December, 2004.



Stephen A. Slusher, Reg. No. 43,924

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/049,579
Filing Date	February 13, 2002
First Named Inventor	Van Asbeck, Bernt
Group Art Unit	1648
Examiner Name	Jeffrey Stucker

Sheet 1 of 1

Attorney Docket No: 30394-1064

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
--------------------	---------------------	------------------	---	---

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
--------------------	---------------------	------------------	---	---	----------------

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ANDRUS, L. , et al., "Antiretroviral Effects of Deoxyhypusyl Hydroxylase Inhibitors: a Hypusine-Dependent Host Cell Mechanism for Replication of Hu", <u>Biochemical Pharmacology</u> (1998 Jun 1) Vol 55, No. 11, (06/01/1998), 1807-18	
		OHTA, K , et al., "Action of a New Mammalian DNA Polymerase Inhibitor Sulfoquinovosyldiacylglycerol", <u>Biological & Pharmaceutical Bulletin</u> (1999 Feb) Vol. 22, No. 2 pp 111-6 Abstract only.	

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached